Abstract
IL-9 is a Th2 cytokine that exerts pleiotropic activities on T cells, B cells, mast cells, hematopoietic progenitors, and lung epithelial cells, but no effect of this cytokine has been reported so far on mononuclear phagocytes. Human blood monocytes preincubated with IL-9 for 24 h before LPS or PMA stimulation exhibited a decreased oxidative burst, even in the presence of IFN-gamma. The inhibitory effect of IL-9 was specifically abolished by anti-hIL-9R mAb, and the presence of IL-9 receptors was demonstrated on human blood monocytes by FACS. IL-9 also down-regulated TNF-alpha and IL-10 release by LPS-stimulated monocytes. In addition, IL-9 strongly up-regulated the production of TGF-beta1 by LPS-stimulated monocytes. The suppressive effect of IL-9 on the respiratory burst and TNF-alpha production in LPS-stimulated monocytes was significantly inhibited by anti-TGF-beta1, but not by anti-IL-10Rbeta mAb. Furthermore, IL-9 inhibited LPS-induced activation of extracellular signal-regulated kinase 1/2 mitogen-activated protein kinases in monocytes through a TGF-beta-mediated induction of protein phosphatase activity. In contrast, IL-4, which exerts a similar inhibitory effect on the oxidative burst and TNF-alpha release by monocytes, acts primarily through a down-regulation of LPS receptors. Thus, IL-9 deactivates LPS-stimulated blood mononuclear phagocytes, and the mechanism of inhibition involves the potentiation of TGF-beta1 production and extracellular signal-regulated kinase inhibition. These findings highlight a new target cell for IL-9 and may account for the beneficial activity of IL-9 in animal models of exaggerated inflammatory response.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adjuvants, Immunologic / antagonists & inhibitors
-
Adjuvants, Immunologic / metabolism
-
Adjuvants, Immunologic / physiology
-
Antibodies, Blocking / pharmacology
-
Antibodies, Monoclonal / pharmacology
-
Cell Membrane / immunology
-
Cell Membrane / metabolism
-
Down-Regulation / immunology
-
Drug Combinations
-
Enzyme Activation / drug effects
-
Enzyme Activation / immunology
-
Enzyme Inhibitors / pharmacology
-
Flavonoids / pharmacology
-
Humans
-
Interferon-gamma / pharmacology
-
Interleukin-10 / antagonists & inhibitors
-
Interleukin-10 / metabolism
-
Interleukin-9 / antagonists & inhibitors
-
Interleukin-9 / metabolism
-
Interleukin-9 / physiology*
-
Lipopolysaccharide Receptors / biosynthesis
-
Lipopolysaccharide Receptors / metabolism
-
Lipopolysaccharides / antagonists & inhibitors
-
Lipopolysaccharides / metabolism
-
Lipopolysaccharides / pharmacology*
-
Macrophage Activation / immunology
-
Mitogen-Activated Protein Kinase 1 / antagonists & inhibitors
-
Mitogen-Activated Protein Kinase 1 / metabolism
-
Mitogen-Activated Protein Kinase 3
-
Mitogen-Activated Protein Kinases / antagonists & inhibitors
-
Mitogen-Activated Protein Kinases / metabolism
-
Monocytes / enzymology
-
Monocytes / immunology*
-
Monocytes / metabolism*
-
Receptors, Interleukin / immunology
-
Receptors, Interleukin-9
-
Respiratory Burst / drug effects
-
Respiratory Burst / immunology*
-
Transforming Growth Factor beta / biosynthesis
-
Transforming Growth Factor beta / physiology*
-
Transforming Growth Factor beta1
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
-
Tumor Necrosis Factor-alpha / biosynthesis
-
Tumor Necrosis Factor-alpha / metabolism*
Substances
-
Adjuvants, Immunologic
-
Antibodies, Blocking
-
Antibodies, Monoclonal
-
Drug Combinations
-
Enzyme Inhibitors
-
Flavonoids
-
IL9R protein, human
-
Interleukin-9
-
Lipopolysaccharide Receptors
-
Lipopolysaccharides
-
Receptors, Interleukin
-
Receptors, Interleukin-9
-
TGFB1 protein, human
-
Transforming Growth Factor beta
-
Transforming Growth Factor beta1
-
Tumor Necrosis Factor-alpha
-
Interleukin-10
-
Interferon-gamma
-
Mitogen-Activated Protein Kinase 1
-
Mitogen-Activated Protein Kinase 3
-
Mitogen-Activated Protein Kinases
-
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one